# Spyre Therapeutics Inc. (SYRE)

Source: https://www.quantisnow.com/company/SYRE
Generated: 2026-11-15T00:03:02.840Z

- Ticker: SYRE
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2016
- SEC CIK: 0001636282

## Latest SYRE news and filings

- 2026-11-10 13:00 UTC [Conference Announcement] [Spyre Therapeutics to Participate in Upcoming Investor Conferences](https://www.quantisnow.com/insight/spyre-therapeutics-to-participate-in-upcoming-investor-conferences-6782962)
- 2026-11-06 21:05 UTC [Spyre Therapeutics Announces Grants of Inducement Awards](https://www.quantisnow.com/insight/spyre-therapeutics-announces-grants-of-inducement-awards-6778817)
- 2026-11-03 21:02 UTC [SEC Form 8-K] [Spyre Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/spyre-therapeutics-inc-filed-sec-form-8-k-results-of-operations-6769376)
- 2026-11-03 21:01 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Spyre Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-spyre-therapeutics-inc-6769353)
- 2026-11-03 21:01 UTC [Earnings] [Spyre Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update](https://www.quantisnow.com/insight/spyre-therapeutics-reports-third-quarter-2026-financial-results-and-provides-6769317)
- 2026-10-18 13:30 UTC [Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026](https://www.quantisnow.com/insight/spyre-therapeutics-announces-clinical-and-preclinical-data-presentations-at-united-6749720)
- 2026-10-12 12:54 UTC [Analyst Coverage Initiated] [UBS initiated coverage on Spyre Therapeutics with a new price target](https://www.quantisnow.com/insight/ubs-initiated-coverage-on-spyre-therapeutics-with-a-new-price-6743603)
- 2026-10-07 12:00 UTC [SEC Form 8-K] [SEC Form 8-K filed by Spyre Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-spyre-therapeutics-inc-6739773)
- 2026-10-06 20:41 UTC [SEC Form 424B5] [SEC Form 424B5 filed by Spyre Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-spyre-therapeutics-inc-6739188)
- 2026-10-06 00:13 UTC [Public Offering] [Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock](https://www.quantisnow.com/insight/spyre-therapeutics-announces-pricing-of-3500-million-public-offering-of-6737819)
- 2026-10-05 20:10 UTC [SEC Form 424B5] [SEC Form 424B5 filed by Spyre Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-spyre-therapeutics-inc-6736857)
- 2026-10-05 20:01 UTC [Public Offering] [Spyre Therapeutics Announces Proposed Public Offering of its Common Stock](https://www.quantisnow.com/insight/spyre-therapeutics-announces-proposed-public-offering-of-its-common-stock-6736638)
- 2026-10-03 01:30 UTC [SEC Form 4] [Officer King-Jones Heidy exercised 28,933 shares at a strike of $14.50 and sold $2,633,902 worth of shares (28,933 units at $91.03) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/officer-king-jones-heidy-exercised-28933-shares-at-a-strike-of-6735696)
- 2026-10-03 01:29 UTC [SEC Form 4] [Chief Executive Officer Turtle Cameron sold $1,380,105 worth of shares (15,000 units at $92.01) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 537,540 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-turtle-cameron-sold-1380105-worth-of-shares-6735695)
- 2026-10-03 01:29 UTC [SEC Form 4] [Chief Financial Officer Burrows Scott L exercised 25,000 shares at a strike of $14.50 and sold $2,261,831 worth of shares (25,000 units at $90.47) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-burrows-scott-l-exercised-25000-shares-at-6735693)
- 2026-10-02 20:05 UTC [Spyre Therapeutics Announces Grants of Inducement Awards](https://www.quantisnow.com/insight/spyre-therapeutics-announces-grants-of-inducement-awards-6734289)
- 2026-10-01 12:44 UTC [Analyst Coverage Initiated] [Analyst initiated coverage on Spyre Therapeutics with a new price target](https://www.quantisnow.com/insight/analyst-initiated-coverage-on-spyre-therapeutics-with-a-new-price-6731670)
- 2026-09-08 12:01 UTC [SEC Form 8-K] [Spyre Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/spyre-therapeutics-inc-filed-sec-form-8-k-regulation-fd-disclosure-6707600)
- 2026-09-08 12:00 UTC [Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations](https://www.quantisnow.com/insight/spyre-announces-potential-best-in-class-spy003-anti-il-23-part-a-induction-results-6707565)
- 2026-09-04 20:01 UTC [Spyre Therapeutics Announces Grants of Inducement Awards](https://www.quantisnow.com/insight/spyre-therapeutics-announces-grants-of-inducement-awards-6706637)
- 2026-09-04 01:34 UTC [SEC Form 4] [Officer King-Jones Heidy exercised 28,399 shares at a strike of $14.50 and sold $2,480,529 worth of shares (28,399 units at $87.35) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/officer-king-jones-heidy-exercised-28399-shares-at-a-strike-of-6706053)
- 2026-09-04 01:33 UTC [SEC Form 4] [Chief Financial Officer Burrows Scott L exercised 7,500 shares at a strike of $14.50 and sold $2,283,821 worth of shares (25,732 units at $88.75) as part of a pre-agreed trading plan, decreasing direct ownership by 19% to 79,762 units (SEC Form 4) (for tax liability)](https://www.quantisnow.com/insight/chief-financial-officer-burrows-scott-l-exercised-7500-shares-at-6706052)
- 2026-09-04 01:33 UTC [SEC Form 4] [Chief Executive Officer Turtle Cameron sold $1,309,410 worth of shares (15,000 units at $87.29) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 552,540 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-turtle-cameron-sold-1309410-worth-of-shares-6706051)
- 2026-09-03 20:05 UTC [Conference Announcement] [Spyre Therapeutics to Participate in Upcoming September Investor Conferences](https://www.quantisnow.com/insight/spyre-therapeutics-to-participate-in-upcoming-september-investor-conferences-6704945)
- 2026-08-25 20:04 UTC [SEC Form 8-K] [Spyre Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/spyre-therapeutics-inc-filed-sec-form-8-k-regulation-fd-disclosure-6694182)
- 2026-08-25 20:01 UTC [Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072](https://www.quantisnow.com/insight/spyre-therapeutics-announces-topline-results-from-the-rheumatoid-arthritis-sub-study-6694108)
- 2026-08-14 21:22 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Spyre Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-spyre-therapeutics-inc-6683737)
- 2026-08-14 12:10 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Spyre Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-spyre-therapeutics-inc-6681922)
- 2026-08-11 01:31 UTC [SEC Form 4] [Director Albers Jeffrey W. exercised 5,000 shares at a strike of $10.39 and sold $2,404,190 worth of shares (23,000 units at $104.53) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/director-albers-jeffrey-w-exercised-5000-shares-at-a-strike-6674594)
- 2026-08-10 12:00 UTC [Spyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis Suppurativa](https://www.quantisnow.com/insight/spyre-therapeutics-announces-launch-of-spy772-program-and-initiation-of-6672766)
- 2026-08-07 20:05 UTC [Spyre Therapeutics Announces Grants of Inducement Awards](https://www.quantisnow.com/insight/spyre-therapeutics-announces-grants-of-inducement-awards-6671423)
- 2026-08-06 01:32 UTC [SEC Form 4] [Chief Financial Officer Burrows Scott L exercised 7,500 shares at a strike of $14.50 and sold $716,771 worth of shares (7,500 units at $95.57) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-burrows-scott-l-exercised-7500-shares-at-6666687)
- 2026-08-06 01:31 UTC [SEC Form 4] [Chief Executive Officer Turtle Cameron sold $1,432,705 worth of shares (15,000 units at $95.51) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 567,540 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-turtle-cameron-sold-1432705-worth-of-shares-6666686)
- 2026-08-04 20:05 UTC [SEC Form 8-K] [Spyre Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/spyre-therapeutics-inc-filed-sec-form-8-k-results-of-operations-6662074)
- 2026-08-04 20:02 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Spyre Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-spyre-therapeutics-inc-6661919)
- 2026-07-28 12:06 UTC [Analyst Downgrade] [Spyre Therapeutics downgraded by Wolfe Research](https://www.quantisnow.com/insight/spyre-therapeutics-downgraded-by-wolfe-research-6650757)
- 2026-07-03 01:33 UTC [SEC Form 4] [Chief Financial Officer Burrows Scott L exercised 7,500 shares at a strike of $14.50 and sold $658,040 worth of shares (7,500 units at $87.74) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-burrows-scott-l-exercised-7500-shares-at-6626989)
- 2026-07-03 01:33 UTC [SEC Form 4] [Chief Medical Officer Sloan Sheldon exercised 8,334 shares at a strike of $27.46 and sold $730,896 worth of shares (8,334 units at $87.70) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/chief-medical-officer-sloan-sheldon-exercised-8334-shares-at-a-6626988)
- 2026-07-03 01:32 UTC [SEC Form 4] [Chief Executive Officer Turtle Cameron sold $1,315,346 worth of shares (15,000 units at $87.69) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 582,540 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-turtle-cameron-sold-1315346-worth-of-shares-6626986)
- 2026-07-02 20:05 UTC [Spyre Therapeutics Announces Grants of Inducement Awards](https://www.quantisnow.com/insight/spyre-therapeutics-announces-grants-of-inducement-awards-6625069)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/SYRE
- Earnings history: https://www.quantisnow.com/earnings/SYRE
- Dividend history: https://www.quantisnow.com/dividends/SYRE
- Insider transactions: https://www.quantisnow.com/insiders/SYRE
- Options chain: https://www.quantisnow.com/options/SYRE
- SEC 8-K filings only: https://www.quantisnow.com/company/SYRE/8-k
- RSS and alerts for SYRE: https://www.quantisnow.com/docs/rss-feeds.md